Geron Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Geron stock.
View analyst ratings for Geron or view top-rated stocks.

Wall Street analysts have given Geron a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Geron wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Geron is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Geron.

Geron Co. (NASDAQ:GERN) announced its quarterly earnings results on Sunday, May, 9th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.01. The biopharmaceutical company earned $0.14 million during the quarter, compared to analysts' expectations of $0.08 million. Geron had a negative net margin of 25,765.09% and a negative trailing twelve-month return on equity of 38.89%.
View Geron's earnings history.

Geron's stock was trading at $1.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GERN stock has increased by 20.9% and is now trading at $1.2450.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued twelve-month target prices for Geron's shares. Their forecasts range from $3.00 to $7.00. On average, they anticipate Geron's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 301.6% from the stock's current price.
View analysts' price targets for Geron or view top-rated stocks among Wall Street analysts.

5 employees have rated Geron CEO John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among Geron's employees.

Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of GERN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), OrganiGram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO).

Geron trades on the NASDAQ under the ticker symbol "GERN."

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GERN stock can currently be purchased for approximately $1.25.

Geron has a market capitalization of $396.62 million and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-75,620,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.

Geron employs 53 workers across the globe.

The official website for Geron is www.geron.com.

Geron is headquartered at 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404.

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]